LifeMD Inc (NASDAQ:LFMD), a telehealth provider, reported its fourth quarter and full-year 2025 financial results after the market close on Monday, March 9, 2026. The company's performance presented a mixed picture, with strong full-year growth overshadowed by a quarterly revenue miss and ongoing losses, triggering a significant after-hours market reaction.
Quarterly Results Versus Estimates
The core of the market's immediate focus was the company's fourth-quarter performance relative to Wall Street's expectations. LifeMD fell short on the top line while its bottom-line loss was slightly wider than anticipated.
- Revenue: The company reported Q4 2025 revenue of $46.9 million. This represented a 4% year-over-year increase but missed the analyst consensus estimate of approximately $49.5 million.
- Earnings Per Share (EPS): LifeMD reported a non-GAAP net loss per share of $0.04 for the quarter. This was slightly worse than the estimated loss of $0.034 per share that analysts had projected.
The dual miss on both revenue and earnings likely served as the primary catalyst for the negative investor sentiment observed after the report was released.
Market Reaction to the Earnings Release
The market's response to the earnings report was decisively negative. In after-hours trading following the announcement, LifeMD's stock price declined by approximately 13.4%. This sharp drop indicates that investors were disappointed with the quarterly results, particularly the revenue shortfall. The reaction suggests the market was anticipating stronger growth to close out the fiscal year and may be concerned about the company's near-term trajectory as it heads into 2026.
Full-Year 2025 Highlights and Forward Outlook
While the quarterly figures drove the immediate sell-off, the full-year 2025 results told a more robust story of growth and improved profitability. For the entire year, LifeMD achieved revenue of $194.1 million, a 25% increase over 2024. More notably, the company's adjusted EBITDA surged 309% to $15.3 million, signaling significant progress toward operational efficiency and profitability on an adjusted basis.
The press release did not provide specific financial guidance for the upcoming year. However, current analyst estimates offer a benchmark for future expectations. Analysts are forecasting sales of $228.5 million for the full year 2026, which would imply a growth rate of roughly 18% from the 2025 base. For the first quarter of 2026, the consensus sales estimate stands at $51.1 million. The company's ability to meet or exceed these estimates, particularly after the Q4 revenue miss, will be a key focus for investors in the coming quarters.
Press Release Summary
The earnings announcement highlighted several key achievements beyond the financial figures:
- Strong Full-Year Growth: Emphasis was placed on the 25% annual revenue growth and the triple-digit percentage increase in adjusted EBITDA.
- Platform Expansion: LifeMD noted the continued expansion of its telehealth platform, which now offers access to care across 200 conditions.
- Vertical Integration: The company underscored the strength of its vertically integrated model, which includes its affiliated medical group, compounding pharmacy, and patient care center.
For a detailed look at LifeMD's historical earnings performance and to view future analyst projections and estimates, you can visit the Earnings and Analyst Forecast pages.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.